NasdaqGS:IMCRBiotechs
Assessing Immunocore Holdings (IMCR) Valuation After Q1 2026 Results And New Phase 3 Survival Data
Immunocore Holdings (IMCR) is back in focus after reporting Q1 2026 results, with revenue of US$106.68 million, net income of US$12.97 million, and diluted EPS of US$0.25 from continuing operations.
See our latest analysis for Immunocore Holdings.
The Q1 2026 update arrived alongside a sharp 1 day share price return of 6.55% and a 7 day share price return of 10.06%. However, the year to date share price return of negative 9.03% and 3 year total shareholder return of negative 48.66% show that...